Is Ardelyx, Inc. (ARDX) a Buy? The Stock Rises Again

April 17, 2018 - By Linda Rogers

Ardelyx, Inc. (NASDAQ:ARDX) Logo

The stock of Ardelyx, Inc. (NASDAQ:ARDX) is a huge mover today! The stock increased 12.75% or $0.65 during the last trading session, reaching $5.75. About 571,015 shares traded or 87.68% up from the average. Ardelyx, Inc. (NASDAQ:ARDX) has declined 60.67% since April 17, 2017 and is downtrending. It has underperformed by 72.22% the S&P500.
The move comes after 8 months positive chart setup for the $273.72M company. It was reported on Apr, 17 by Barchart.com. We have $6.10 PT which if reached, will make NASDAQ:ARDX worth $16.42 million more.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. The company has market cap of $273.72 million. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It currently has negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.

Ardelyx, Inc. (NASDAQ:ARDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.